These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32220214)

  • 1. Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis.
    Samjoo IA; Worthington E; Haltner A; Cameron C; Nicholas R; Rouyrre N; Dahlke F; Adlard N
    Curr Med Res Opin; 2020 Jul; 36(7):1157-1166. PubMed ID: 32220214
    [No Abstract]   [Full Text] [Related]  

  • 2. The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis.
    Samjoo IA; Worthington E; Haltner A; Cameron C; Nicholas R; Dahlke F; Adlard N
    Curr Med Res Opin; 2020 Jul; 36(7):1145-1156. PubMed ID: 32216597
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland.
    Schur N; Gudala K; Vudumula U; Vadapalle S; Bhadhuri A; Casanova A; Adlard N; Schwenkglenks M
    Pharmacoeconomics; 2021 May; 39(5):563-577. PubMed ID: 33791945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK.
    Montgomery S; Woodhouse F; Vudumula U; Gudala K; Duddy M; Kroes M
    J Med Econ; 2022; 25(1):669-678. PubMed ID: 35575251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
    Kappos L; Bar-Or A; Cree BAC; Fox RJ; Giovannoni G; Gold R; Vermersch P; Arnold DL; Arnould S; Scherz T; Wolf C; Wallström E; Dahlke F;
    Lancet; 2018 Mar; 391(10127):1263-1273. PubMed ID: 29576505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis].
    Evdoshenko EP; Neofidov NA; Bakhtiyarova KZ; Davydovskaya MV; Kairbekova EI; Kolontareva YM; Malkova NA; Odinak MM; Popova EV; Sazonov DV; Stolyarov ID; Smagina IV; Fedyanin AS; Habirov FA; Khaibullin TI; Khachanova NV; Shchukin IA; Boyko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):110-119. PubMed ID: 31934996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
    Benedict RHB; Tomic D; Cree BA; Fox R; Giovannoni G; Bar-Or A; Gold R; Vermersch P; Pohlmann H; Wright I; Karlsson G; Dahlke F; Wolf C; Kappos L
    Neurology; 2021 Jan; 96(3):e376-e386. PubMed ID: 33328324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study.
    Hua LH; Bar-Or A; Cohan SL; Lublin FD; Coyle PK; Cree BA; Meng X; Su W; Cox GM; Fox RJ
    Mult Scler Relat Disord; 2023 Jul; 75():104766. PubMed ID: 37245350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses.
    Samjoo IA; Worthington E; Haltner A; Spin P; Drudge C; Cameron C; Brennan R; Dahlke F; Adlard N
    Curr Med Res Opin; 2021 Nov; 37(11):1933-1944. PubMed ID: 34384311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
    Gold R; Piani-Meier D; Kappos L; Bar-Or A; Vermersch P; Giovannoni G; Fox RJ; Arnold DL; Benedict RHB; Penner IK; Rouyrre N; Kilaru A; Karlsson G; Ritter S; Dahlke F; Hach T; Cree BAC
    J Neurol; 2022 Sep; 269(9):5093-5104. PubMed ID: 35639197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
    Cree BA; Arnold DL; Fox RJ; Gold R; Vermersch P; Benedict RH; Bar-Or A; Piani-Meier D; Rouyrre N; Ritter S; Kilaru A; Karlsson G; Giovannoni G; Kappos L
    Mult Scler; 2022 Sep; 28(10):1591-1605. PubMed ID: 35380078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
    Cohan S; Kumar J; Arndorfer S; Zhu X; Zivkovic M; Tencer T
    CNS Drugs; 2021 Jul; 35(7):795-804. PubMed ID: 33847901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy.
    Cortesi PA; Antonazzo IC; Gasperini C; Nica M; Ritrovato D; Mantovani LG
    PLoS One; 2022; 17(3):e0264123. PubMed ID: 35259168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
    Cree BA; Magnusson B; Rouyrre N; Fox RJ; Giovannoni G; Vermersch P; Bar-Or A; Gold R; Piani Meier D; Karlsson G; Tomic D; Wolf C; Dahlke F; Kappos L
    Mult Scler; 2021 Sep; 27(10):1564-1576. PubMed ID: 33205682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
    Cadavid D; Jurgensen S; Lee S
    PLoS One; 2013; 8(1):e53297. PubMed ID: 23308186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Siponimod: a new view at the therapy of secondary progressive multiple sclerosis].
    Krasnov VS; Kolontareva YM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7):124-129. PubMed ID: 34460168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
    Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
    Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
    [No Abstract]   [Full Text] [Related]  

  • 18. [Disease-modifying treatment of secondary progressive multiple sclerosis].
    Hoffmann O; Gold R
    Nervenarzt; 2021 Oct; 92(10):1052-1060. PubMed ID: 33656569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
    Panitch H; Miller A; Paty D; Weinshenker B;
    Neurology; 2004 Nov; 63(10):1788-95. PubMed ID: 15557491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
    Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B
    Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.